Management of Glanzmann Thrombasthenia
For acute bleeding in Glanzmann thrombasthenia, use recombinant factor VIIa (rFVIIa) at 80-120 µg/kg as first-line therapy, with antifibrinolytics (tranexamic acid) as adjunctive treatment, reserving platelet transfusions for life-threatening bleeding or rFVIIa failure to minimize alloimmunization risk 1.
Acute Bleeding Management Algorithm
First-Line Treatment
- rFVIIa dosing: 80-120 µg/kg bolus, repeat every 2 hours during interventions 1
- Success rate: 91% when used alone, 82.7% when combined with antifibrinolytics 2
- This approach is particularly critical for patients with antibodies to HLA and/or GPIIb/IIIa 1
Adjunctive Therapy
- Tranexamic acid (antifibrinolytics): Use routinely alongside rFVIIa
Second-Line Treatment
- Platelet transfusions: Reserve for:
- Life-threatening bleeding unresponsive to rFVIIa
- Situations where rFVIIa is unavailable
- Success rate: 78.8% for platelets ± antifibrinolytics 2
Critical caveat: Platelet transfusions carry significant risk of anti-platelet antibody formation, leading to platelet-refractory disease 5. This complication makes future bleeding episodes exponentially harder to manage. Use HLA-matched platelets when transfusion is necessary to reduce alloimmunization 6.
Long-Term Management Strategy
Preventive Measures
- Iron supplementation: All patients develop iron deficiency from chronic bleeding 7
- Erythropoietin: For maintaining hemoglobin levels without transfusion 7
- Hormonal management for females:
Monitoring Protocol
- Baseline hemoglobin: Often severely low at diagnosis (mean 5.6 g/dL) 7
- Target hemoglobin: Achievable mean of 11 g/dL with non-transfusion methods 7
- Antibody screening: Monitor for anti-platelet antibodies every 4-6 weeks, especially during pregnancy 6
Transfusion Avoidance Strategy
Approximately 70% of patients can avoid blood transfusions over 5-year periods using aggressive non-transfusion management 7. This approach prevents:
- Transfusion-related adverse events
- Immunomodulation complications
- Alloimmunization
- High treatment costs 7
Special Situations
Perioperative Management
- Preoperative: rFVIIa 80-120 µg/kg before procedure 1
- Intraoperative: Repeat dosing every 2 hours as needed 1
- Requirements for rFVIIa efficacy:
- Fibrinogen ≥1 g/L
- Platelet count ≥50 × 10⁹/L
- pH ≥7.2
- Temperature >34°C 1
Pregnancy and Delivery
- Multidisciplinary coordination essential (maternal-fetal medicine, hematology, transfusion medicine, anesthesiology) 6
- Prioritize uterotonics and tranexamic acid for postpartum hemorrhage 6
- Serial monitoring for neonatal alloimmune thrombocytopenia risk 6
- HLA-matched platelets if transfusion required 6
Evidence Quality Considerations
The guideline evidence 1 from the International Society on Thrombosis and Haemostasis (2018) provides the dosing framework, while the prospective Glanzmann Thrombasthenia Registry 2 offers the strongest real-world efficacy data with 829 bleeding episodes analyzed. The 2023 French consensus recommendations 8 and recent multi-center studies 4 confirm these approaches remain current standard of care.
Treatment failure occurs in only 2% of cases 2, with bleeding recurrence in 6% after initial control. No thromboembolic events were reported with rFVIIa use in the registry 2, addressing a theoretical safety concern.
Diagnostic Confirmation
Diagnosis requires platelet aggregation studies, flow cytometry for CD41/CD61 expression, and genetic sequencing of ITGA2B/ITGB3 5. However, no correlation exists between CD41/CD61 expression levels and bleeding severity or treatment response 4, meaning all three GT types (I, II, III) require identical management approaches.